Cargando…

Dual Inhibition of BRAF-MAPK and STAT3 Signaling Pathways in Resveratrol-Suppressed Anaplastic Thyroid Cancer Cells with BRAF Mutations

Anaplastic thyroid cancer is an extremely lethal malignancy without reliable treatment. BRAFV600E point mutation is common in ATCs, which leads to MAPK signaling activation and is regarded as a therapeutic target. Resveratrol inhibits ATC cell growth, while its impact on BRAF-MAPK signaling remains...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lu, Meng-Di, Li, Hong, Nie, Jun-Hua, Li, Sheng, Ye, Hai-Shan, Li, Ting-Ting, Wu, Mo-Li, Liu, Jia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9692422/ https://www.ncbi.nlm.nih.gov/pubmed/36430869 http://dx.doi.org/10.3390/ijms232214385

Ejemplares similares

Rare Manifestations of Anaplastic Thyroid Carcinoma: the Role of BRAF Mutation Analysis
por: Song, Young Shin, et al.
Publicado: (2017)

Dual EGFR and BRAF blockade overcomes resistance to vemurafenib in BRAF mutated thyroid carcinoma cells
por: Notarangelo, Tiziana, et al.
Publicado: (2017)

BRAF(V600E) mutation in anaplastic thyroid carcinomas and their accompanying differentiated carcinomas
por: Takano, T, et al.
Publicado: (2007)

Targeted therapy with vemurafenib in BRAF(V600E)-mutated anaplastic thyroid cancer
por: Lang, Matthias, et al.
Publicado: (2023)

Resveratrol Suppresses the Growth and Enhances Retinoic Acid Sensitivity of Anaplastic Thyroid Cancer Cells
por: Li, Yi-Tian, et al.
Publicado: (2018)

Inhibiting ERK dimerization ameliorates BRAF-driven anaplastic thyroid cancer
por: Zaballos, Miguel A., et al.
Publicado: (2022)

Pembrolizumab in a Patient with Treatment-Naïve Unresectable BRAF-Mutation Negative Anaplastic Thyroid Cancer
por: Nabhan, Fadi, et al.
Publicado: (2021)

Dual Inhibition of MAPK and JAK2/STAT3 Pathways Is Critical for the Treatment of BRAF Mutant Melanoma
por: Zhao, Kun, et al.
Publicado: (2020)

Identification of synthetic chemosensitivity genes paired with BRAF for BRAF/MAPK inhibitors
por: Lee, Kye Hwa, et al.
Publicado: (2020)

Resveratrol and its Nanoparticle suppress Doxorubicin/Docetaxel-resistant anaplastic Thyroid Cancer Cells in vitro and in vivo
por: Xiong, Le, et al.
Publicado: (2021)

Sorafenib inhibits vascular endothelial cell proliferation stimulated by anaplastic thyroid cancer cells regardless of BRAF mutation status
por: Ishihara, Sae, et al.
Publicado: (2019)

The Clinicopathological Features of BRAF Mutated Papillary Thyroid Cancers in Chinese Patients
por: Yang, Li-Bo, et al.
Publicado: (2015)

Correlation of Reactive Oxygen Species Levels with Resveratrol Sensitivities of Anaplastic Thyroid Cancer Cells
por: Zheng, Xu, et al.
Publicado: (2018)

BRAF and NRAS Mutations in Papillary Thyroid Carcinoma and Concordance in BRAF Mutations Between Primary and Corresponding Lymph Node Metastases
por: Fakhruddin, Najla, et al.
Publicado: (2017)

Squamous Cell Carcinoma of the Thyroid as a Result of Anaplastic Transformation from BRAF-Positive Papillary Thyroid Cancer
por: Basnet, Alina, et al.
Publicado: (2017)

Epigenetic modification and BRAF gene mutation in thyroid carcinoma
por: Huang, Guo, et al.
Publicado: (2021)

Overcoming Resistance to Therapies Targeting the MAPK Pathway in BRAF-Mutated Tumours
por: Paton, Emily L., et al.
Publicado: (2020)

BRAF/MEK double blockade in refractory anaplastic pleomorphic xanthoastrocytoma
por: Migliorini, Denis, et al.
Publicado: (2017)

Targeting myeloid derived suppressor cells reverts immune suppression and sensitizes BRAF-mutant papillary thyroid cancer to MAPK inhibitors
por: Zhang, Peitao, et al.
Publicado: (2022)

Targeting BRAF in thyroid cancer
por: Espinosa, A V, et al.
Publicado: (2007)

Targeting BRAF in thyroid cancer
por: Espinosa, A V, et al.
Publicado: (2007)

BRAF in Papillary Thyroid Carcinoma
por: Lanzilotta, Salvatore Giovanni, et al.
Publicado: (2007)

Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma
por: Spagnolo, Francesco, et al.
Publicado: (2014)

Complete Surgical Resection Following Neoadjuvant Dabrafenib Plus Trametinib in BRAF(V600E)-Mutated Anaplastic Thyroid Carcinoma
por: Wang, Jennifer R., et al.
Publicado: (2019)

The Impact of BRAF Mutation on the Recurrence of Papillary Thyroid Carcinoma: A Meta-Analysis
por: Li, Xin, et al.
Publicado: (2020)

Melatonin synergizes BRAF‐targeting agent dabrafenib for the treatment of anaplastic thyroid cancer by inhibiting AKT/hTERT signalling
por: Liao, Yina, et al.
Publicado: (2020)

Circulating BRAF V600E Cell-Free DNA as a Biomarker in the Management of Anaplastic Thyroid Carcinoma
por: Iyer, Priyanka C., et al.
Publicado: (2018)

Targeting the BRAF Signaling Pathway in CD133(pos) Cancer Stem Cells of Anaplastic Thyroid Carcinoma
por: Bozorg-Ghalati, Farzaneh, et al.
Publicado: (2019)

BRAF mutations in thyroid tumors from an ethnically diverse group
por: Schulten, Hans-Juergen, et al.
Publicado: (2012)

Disruption of mutated BRAF signaling modulates thyroid cancer phenotype
por: Hanly, Elyse K, et al.
Publicado: (2014)

Circulating Tumor BRAF Mutation and Personalized Thyroid Cancer Treatment
por: Khatami, Fatemeh, et al.
Publicado: (2017)

Association of DNA Promoter Methylation and BRAF Mutation in Thyroid Cancer
por: Jasmine, Farzana, et al.
Publicado: (2023)

Effective MAPK Inhibition is critical for therapeutic responses in colorectal cancer with BRAF mutations
por: Ahronian, Leanne G., et al.
Publicado: (2015)

Intermittent Versus Continuous Dosing of MAPK Inhibitors in the Treatment of BRAF-Mutated Melanoma
por: Reger de Moura, Coralie, et al.
Publicado: (2019)

Anaplastic Lymphoma Kinase Confers Resistance to BRAF Kinase Inhibitors in Melanoma
por: Janostiak, Radoslav, et al.
Publicado: (2019)

OR27-6 Combination Vemurafenib (BRAF Inhibitor)/Cobimetinib (MEK Inhibitor)/Atezolizumab (Anti-PDL1 Inhibitor) in BRAF-V600E Mutated Anaplastic Thyroid Cancer (ATC): Initial Safety and Feasibility
por: Cabanillas, Maria, et al.
Publicado: (2019)

Surgery After BRAF-Directed Therapy Is Associated with Improved Survival in BRAF(V600E) Mutant Anaplastic Thyroid Cancer: A Single-Center Retrospective Cohort Study
por: Zhao, Xiao, et al.
Publicado: (2023)

Clinical implications of the BRAF mutation in papillary thyroid carcinoma and chronic lymphocytic thyroiditis
por: Kim, Woon Won, et al.
Publicado: (2018)

The BRAF V600E mutation is a predictor of the effect of radioiodine therapy in papillary thyroid cancer
por: Ge, Junshang, et al.
Publicado: (2020)

Anaplastic Transformation of Papillary Thyroid Carcinoma in a Young Man: A Case Study with Immunohistochemical and BRAF Analysis
por: Park, Ji Hye, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_s9pnojc85agdiimgso7nmursev